The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

Cited by (404)

Items 101–200 of 404

1. Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice
   Christina Unger Lithner, Marie M. Svedberg, Wenfeng Yu, Monika M. Hedberg, Agneta K. Nordberg · 2006 · Journal of Pharmacology and Experimental Therapeutics
2. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain
   Catherine E. Creeley, David F. Wozniak, Anthony Nardi, Nuri B. Farber, John W. Olney · 2006 · Neurobiology of Aging
3. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review
   Ranju Bansal, Ranjit Singh · 2017 · Medicinal Research Reviews
4. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis
   Taro Kishi, Shinji Matsunaga, Nakao Iwata · 2017 · Neuropsychiatric Disease and Treatment
5. Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
   Maurice W. Dysken, Peter Guarino, Julia E. Vertrees, Sanjay Asthana, Mary C. Sano, Maria D. Llorente, Muralidhar Pallaki, Susan B. Love, Gerard D. Schellenberg, John Riley McCarten et al. · 2013 · Alzheimer s & Dementia
6. Anesthesia and Postoperative Cognitive Dysfunction (POCD)
   Bettina Jungwirth, W. Zieglgänsberger, Eberhard Friedrich Kochs, Gerhard Rammes · 2009 · Mini-Reviews in Medicinal Chemistry
7. Memantine: efficacy and safety in mild-to-severe Alzheimer's disease
   Rajesh R. Tampi, Christopher H. van Dyck · 2007 · Neuropsychiatric Disease and Treatment
8. Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata
   Wantida Chaiyana, Thomas Rades, Siriporn Okonogi · 2013 · International Journal of Pharmaceutics
9. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
   Reinhold Schmidt, Stefan Ropele, B Pendl, Patrick Ofner, Christian Enzinger, Helena Schmidt, Andrea Berghold, Manfred Windisch, H Kolassa, Franz Fazekas · 2008 · Journal of Neurology Neurosurgery & Psychiatry
10. Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease
    Галина Ф. Махаева, E. F. Shevtsova, Natalia P. Boltneva, Sofya V. Lushchekina, Надежда Владимировна Ковалева, Елена Владимировна Рудакова, Сергей Олегович Бачурин, Rudy J. Richardson · 2019 · Chemico-Biological Interactions
11. Dextromethorphan as a potential rapid-acting antidepressant
    Edward C. Lauterbach · 2011 · Medical Hypotheses
12. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis
    Taro Kishi, Yuki Matsuda, Nakao Iwata · 2017 · Psychopharmacology
13. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice
    Menyang Liu, Samuel R. Wang, Weifan Yao, Z.J. Zhang, Xin Zhong, L. Sha, Miao He, Zhencang ZHENG, M.J. Wei · 2014 · Neuroscience
14. Phytochemicals: A Promising Alternative for the Prevention of Alzheimer’s Disease
    Bhupendra Koul, Usma Farooq, Dhananjay Yadav, Minseok Song · 2023 · Life
15. Clear cell meningioma variant and clinical aggressiveness.
    José Pimentel, A Fernandes, António E. Pinto, Isabel Fonseca, Jose F. Moura Nunes, José Leopoldo Ferreira Antunes · 1998 · PubMed
16. Neuroinflammation
    Deepika Mukhara, Unsong Oh, Gretchen N. Neigh · 2020 · Handbook of clinical neurology
17. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    Doody, R., Wirth, Y., Schmitt, F., Möbius, H.J. · 2004 · Dementia and Geriatric Cognitive Disorders
18. Persistent memories of long-term potentiation and the N -methyl-d-aspartate receptor
    T.V.P. Bliss, Graham L. Collingridge · 2019 · Brain and Neuroscience Advances
19. GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
    A. Ladagu, F. Olopade, Adeboye Adejare, J. Olopade · 2023 · Pharmaceuticals
20. Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model
    Kei Higuchi, Atsushi Kitamura, Takashi Okura, Yoshiharu Deguchi · 2015 · Drug Metabolism and Pharmacokinetics
21. Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction
    Anna Kiryk, Tomomi Aida, Kohichi Tanaka, Pradeep Banerjee, Grzegorz Marek Wilczynski, Ksenia Z. Meyza, Ewelina Knapska, Robert Kuba Filipkowski, Leszek Kaczmarek, Wojciech Danysz · 2008 · Neurotoxicity Research
22. The impact of chelating compounds on Cu2+, Fe2+/3+, and Zn2+ ions in Alzheimer's disease treatment
    Tomasz Mazur, Magdalena Malik, Dariusz C. Bieńko · 2024 · Journal of Inorganic Biochemistry
23. Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
    Francesc Xavier Sureda, Fèlix Junyent, Ester Verdaguer, Carme Auladell, Carme Pelegrı́, Jordi Vilaplana, Jaume Folch, Anna Maria Canudas, Carlos Beas Zárate, Mercè Pallàs et al. · 2011 · Current Pharmaceutical Design
24. A Meta-Analysis of Memantine for Depression
    Taro Kishi, Shinji Matsunaga, Nakao Iwata · 2017 · Journal of Alzheimer s Disease
25. Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser‐induced fluorescence detection and its clinical application
    Hsin‐Hua Yeh, Yuan‐Han Yang, Su‐Hwei Chen · 2010 · Electrophoresis
26. The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli
    John C. Talpos, A. C. Fletcher, C. Circelli, Mark David Tricklebank, Sophie L. Dix · 2011 · Psychopharmacology
27. Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
    Patrick D. Roberts, Äthan Spiros, Hugo Geerts · 2012 · Alzheimer s Research & Therapy
28. Hippocampal calcium dysregulation at the nexus of diabetes and brain aging
    Olivier Thibault, Katie L. Anderson, Chris DeMoll, Lawrence D. Brewer, Philip W. Landfield, Nada M. Porter · 2013 · European Journal of Pharmacology
29. Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats
    Paolo Tucci, Emanuela Mhillaj, Maria Grazia Morgese, Marilena Colaianna, Margherita Zotti, Stefania Schiavone, Maria Cicerale, Viviana Trezza, Patrizia Campolongo, V. Cuomo et al. · 2014 · Frontiers in Behavioral Neuroscience
30. Manganese and related neurotoxic pathways: A potential therapeutic target in neurodegenerative diseases
    Shivani Chib, Shamsher Singh · 2022 · Neurotoxicology and Teratology
31. Synergistic Neuroprotection by Bis(7)-tacrine via Concurrent Blockade of N-Methyl-d-aspartate Receptors and Neuronal Nitric-Oxide Synthase
    Wenming Li, Jian Xue, Chunying Niu, Hongjun Fu, Colin S.C. Lam, Jialie Luo, Hugh Hiu Nam Chan, Huaiguo Xue, Kelvin K.W. Kan, Nelson T.K. Lee et al. · 2007 · Molecular Pharmacology
32. On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
    Alberto C. S. Costa · 2011 · Developmental Neuroscience
33. Memantine prevents MDMA-induced neurotoxicity
    Carlos Chipana, Jorge Camarasa, David Pubill, Elena Escubedo · 2007 · NeuroToxicology
34. Bioactive Compounds and Traditional Herbal Medicine: Promising Approaches for the Treatment of Dementia
    Nafaa Alzobaidi, Huma Quasimi, Nasr Ali Emad, Abdulsalam Alhalmi, Maaz Naqvi · 2021 · Degenerative Neurological and Neuromuscular Disease
35. The uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task
    Laura E. Wise, Aron H. Lichtman · 2007 · European Journal of Pharmacology
36. Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease
    Alessandro Tozzi, Alessandra Sclip, Michela Tantucci, Antonio de Iure, Veronica Ghiglieri, Cinzia Costa, Massimiliano Di Filippo, Tiziana Borsello, Paolo Calabresi · 2014 · Neurobiology of Aging
37. Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study
    Jin Yang, Yu Niu, Christa Simon, Andreea L. Seritan, Lawrence Chen, Andrea Schneider, Shayan T. Moghaddam, Paul J. Hagerman, Randi Jenssen Hagerman, John Olichney · 2014 · Neuropsychopharmacology
38. Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer’s Disease Pathogenesis
    Ben Ellis, Abdul Hye, Stuart G. Snowden · 2015 · Journal of Alzheimer s Disease
39. Memantine for the treatment of general neuropathic pain: a narrative review
    Gisele P Pickering, Véronique Morel · 2017 · Fundamental and Clinical Pharmacology
40. Memantine as an Example of a Fast, Voltage-Dependent, Open Channel N-Methyl-d-Aspartate Receptor Blocker
    Chris G. Parsons, Kate E. Gilling · 2007 · Methods in molecular biology
41. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nω-nitro-L-arginine methyl ester
    Bryan D. Devan, Paul J. Pistell, Lee W. Daffin, Christopher M. Nelson, Kara B. Duffy, Jonna L. Bowker, Ila Sri Bharati, Demetrio Sierra‐Mercado, Edward L. Spangler, Donald K. Ingram · 2007 · European Journal of Pharmacology
42. Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases
    Allison Carles, Aline Freyssin, Florent Perin-Dureau, Gilles Rubinstenn, Tangui Maurice · 2024 · International Journal of Molecular Sciences
43. From Plaques to Pathways in Alzheimer’s Disease: The Mitochondrial-Neurovascular-Metabolic Hypothesis
    Kazemeini, Sarah, Nadeem-Tariq, Ahmed, Shih, Ryan, Rafanan, John, Ghani, Nabih, Vida, Thomas A. · 2024 · International Journal of Molecular Sciences
44. Current Therapeutic Targets for Alzheimer's Disease
    Amit Chaudhary, Pramod Kumar Maurya, Birendra Singh Yadav, Swati Singh, Ashutosh Mani · 2018 · Journal of Biomedicine
45. Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
    Matthew J. Sharman, Giuseppe Verdile, Kirubakaran Shanmugam, Cristina Parenti, Ahilya Singh, Georgia Watt, Tim Karl, Dennis Chang, Chun Guang Li, Gerald W Münch · 2019 · CNS Drugs
46. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats
    Lorenzo Morè, Andreas Gravius, Jens Nagel, Barbara Valastro, Sergio Greco, Wojciech Danysz · 2008 · Behavioural Pharmacology
47. Memantine
    Greg L. Plosker, Katherine Ann Lyseng-Williamson · 2005 · PharmacoEconomics
48. Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats
    Shawn E. Kotermanski, Jon W. Johnson, Edda Thiels · 2013 · Pharmacology Biochemistry and Behavior
49. Memantine prevents aluminum-induced cognitive deficit in rats
    Raafat A. Abdel‐Aal, Abdel-Azim A. Assi, Botros B. Kostandy · 2011 · Behavioural Brain Research
50. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease
    Nazem Bassil, Papan Thaipisuttikul, George Thomas Grossberg · 2010 · Expert Opinion on Pharmacotherapy
51. Brain Distribution and Modulation of Neuronal Excitability by Indicaxanthin From Opuntia Ficus Indica Administered at Nutritionally-Relevant Amounts
    Giuditta Gambino, Mario Allegra, Pierangelo Sardo, Alessandro Attanzio, Luisa Tesoriere, Maria Antonietta Livrea, Giuseppe Ferraro, Fabio Carletti · 2018 · Frontiers in Aging Neuroscience
52. Therapeutic Approaches to Alzheimer’s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection
    Rajeev Taliyan, Sarathlal Kalarikkal Chandran, Violina Kakoty · 2019 · Current Pharmaceutical Design
53. MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a “brain tonic”
    Adriana Lourenço da Silva, Bárbara da Silva Martins, Viviane de Moura Linck, Ana Paula Herrmann, Nathalia Mai, Domingos Sávio Nunes, Elaine Elisabetsky · 2008 · Psychopharmacology
54. Disability in multiple sclerosis: When synaptic long-term potentiation fails
    Sagit Weiss, Francesco Mori, Silvia Rossi, Diego Centonze · 2014 · Neuroscience & Biobehavioral Reviews
55. Memantine for Lewy Body Disorders: Systematic Review and Meta-Analysis
    Shinji Matsunaga, Taro Kishi, Nakao Iwata · 2013 · American Journal of Geriatric Psychiatry
56. Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways
    Guijun Song, YU LI, Lu‐Lu Lin, Yunpeng Cao · 2015 · Molecular Medicine Reports
57. Improvement of contextual memory by S 24795 in aged mice: comparison with memantine
    Daniel Béracochéa, Aurélie Boucard, C. Trocmé, Philippe Morain · 2007 · Psychopharmacology
58. A detailed insight into the interaction of memantine with bovine serum albumin: A spectroscopic and computational approach
    Faisal Ameen, Sharmin Siddiqui, Ishrat Jahan, Shahid M. Nayeem, Sayeed Ur Rehman, Mohammad Tabish · 2020 · Journal of Molecular Liquids
59. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease
    Brian R. Ott, Lesley M. Blake, Ethel Kagan, Malca Resnick, for the Memantine MEM-MD-11AB Study Group · 2007 · Journal of Neurology
60. The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats
    Duygu Çakıl, Mehmet Yıldırım, Mustafa Ayyıldız, Erdal Ağar · 2010 · Epilepsy Research
61. Efficacy and tolerability of memantine in the treatment of dementia
    Rebecca C. Rossom, Adityanjee, Maurice W. Dysken · 2004 · The American Journal of Geriatric Pharmacotherapy
62. The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons
    Monika Sharma, Pankaj Pal, Sukesh Kumar Gupta · 2024 · Brain Research
63. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
    Kanzal Iman, Muhammad Usman Mirza, Nauman Mazhar, Michiel Vanmeert, Imran Irshad, Mohammad Amjad Kamal · 2018 · CNS & Neurological Disorders - Drug Targets
64. High-frequency repetitive transcranial magnetic stimulation improves spatial episodic learning and memory performance by regulating brain plasticity in healthy rats
    Qi Wu, Xingjun Xu, Chenyuan Zhai, Zhiyong Zhao, Wenjun Dai, Tong Wang, Ying Shen · 2022 · Frontiers in Neuroscience
65. Inhibition of the α9α10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-d-aspartate receptors
    Paola V. Plazas, Jessica Savino, Sebastian Kracun, María Eugenia Gómez‐Casati, Eleonora Katz, Christopher G. Parsons, Neil S. Millar, Ana Belén Elgoyhen · 2007 · European Journal of Pharmacology
66. Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β1–40
    José Javier Miguel-Hidalgo, Ian A. Paul, Valerie Wanzo, Pradeep Banerjee · 2012 · European Journal of Pharmacology
67. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats
    Gislaine Z. Réus, Samira Silva Valvassori, Roberta Albino Machado, Márcio R. Martins, Elaine Cristina Gavioli, João Quevedo · 2007 · Naunyn-Schmiedeberg s Archives of Pharmacology
68. The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP)
    Gerhard Rammes, Franziska Seeser, Korinna Mattusch, Kaichuan Zhu, Laura T. Haas, Markus P. Kummer, Michael Thomas Heneka, Jochen Wolfgang Herms, Chris G. Parsons · 2018 · Neuropharmacology
69. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease
    Frederick A. Schmitt, Melody Ann Ryan, Gregory E. Cooper · 2007 · Expert Opinion on Drug Metabolism & Toxicology
70. Promising tacrine/huperzine A‐based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget
    Shinghung Mak, Wenming Li, Hongjun Fu, Jialie Luo, Wei Cui, Shengquan Hu, Yuan‐Ping Pang, Paul R. Carlier, Karl Wah Keung Tsim, Rongbiao Pi et al. · 2021 · Journal of Neurochemistry
71. P4‐193: COMBINATION THERAPY WITH CHOLINESTERASE INHIBITORS AND MEMANTINE FOR ALZHEIMER'S DISEASE: SYSTEMATIC REVIEW AND META‐ANALYSIS
    Shinji Matsunaga, Taro Kishi, Nakao Iwata · 2014 · Alzheimer s & Dementia
72. Integrated phytochemical analysis based on UHPLC-LTQ–Orbitrap and network pharmacology approaches to explore the potential mechanism of Lycium ruthenicum Murr. for ameliorating Alzheimer's disease
    Zhiqiang Luo, Guohua Yu, Xinjing Chen, Yang Liu, Yating Zhou, Guopeng Wang, Yuanyuan Shi · 2020 · Food & Function
73. Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus
    Ernesto Tarragón, Dolores Lopez, Cristina M. Estrada, Ana María González Cuello, Carmen Ma Ros, Yves Lamberty, Fabien Pifferi, Massimo Cella, Mara Canovi, Giovanna Guiso et al. · 2014 · Neuropharmacology
74. Computational studies of NMDA receptors: differential effects of neuronal activity on efficacy of competitive and noncompetitive antagonists
    Michel Baudry · 2010 · Open Access Bioinformatics
75. Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists
    A. S. Sklyarova, V. N. Rodionov, Christopher G. Parsons, G. Quack, Peter R. Schreiner, Andrey A. Fokin · 2012 · Medicinal Chemistry Research
76. Inflammation and aging: Can endocannabinoids help?
    Yannick Marchalant, Holly M. Brothers, Gary L. Wenk · 2008 · Biomedicine & Pharmacotherapy
77. Isoxazoles: synthesis, evaluation and bioinformatic design as acetylcholinesterase inhibitors
    Margarita Gutiérrez, María Francisca Matus, T. Poblete, Jessica Amigo, Gabriel A. Vallejos, Luis A. Astudillo · 2013 · Journal of Pharmacy and Pharmacology
78. HIV ‐1 Tat activates a RhoA signaling pathway to reduce NMDA ‐evoked calcium responses in hippocampal neurons via an actin‐dependent mechanism
    Kelly A. Krogh, Elizabeth Lyddon, Stanley A. Thayer · 2014 · Journal of Neurochemistry
79. Efficacy and safety of memantine in Lewy body dementia
    Oleg Semenovich Levin, L. A. Batukaeva, Смоленцева Ирина Геннадьевна, Н. А. Амосова · 2009 · Neuroscience and Behavioral Physiology
80. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine
    Kate E. Gilling, Claudia Jatzke, Chris G. Parsons · 2007 · Neuropharmacology
81. Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and l -Cysteine Supplementation
    Sushil Kumar Jain, Christopher M. Stevens, Jeffrey Justin Margret, Steven N. Levine · 2023 · Antioxidants and Redox Signaling
82. The Gut-Brain Axis and Neuroinflammation in Traumatic Brain Injury
    Mega Obukohwo Oyovwi, Onoriode Andrew Udi · 2024 · Molecular Neurobiology
83. Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists
    Bjoern Krueger, Tanja Weil, Gisbert Schneider · 2009 · Journal of Computer-Aided Molecular Design
84. Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases
    Dazhi Liu, Bradley P. Ander, Frank R. Sharp · 2009 · Neurobiology of Disease
85. Enhancement of Morphological Plasticity in Hippocampal Neurons by a Physically Modified Saline via Phosphatidylinositol-3 Kinase
    Avik Roy, Khushbu K. Modi, Saurabh Khasnavis, Supurna Ghosh, Richard L. Watson, Kalipada Pahan · 2014 · PLoS ONE
86. Modulation of N-Methyl-d-aspartate Receptors by Donepezil in Rat Cortical Neurons
    Shigeki Moriguchi, Xilong Zhao, William Marszalec, Jay Z. Yeh, Toshio Narahashi · 2005 · Journal of Pharmacology and Experimental Therapeutics
87. Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone.
    Zofia Danilczuk, Grażyna Ossowska, Tomasz Lupina, Katarzyna Cieślik, I Zebrowska-Łupina · 2005 · PubMed
88. New symptomatic strategies in Alzheimer's disease
    Christopher N. Johnson, Alexander Roland, Neil Upton · 2004 · Drug Discovery Today Therapeutic Strategies
89. Medha Plus – A novel polyherbal formulation ameliorates cognitive behaviors and disease pathology in models of Alzheimer’s disease
    Ramesh Kumar Paidi, Sukanya Sarkar, Naqiya Ambareen, Subhas Chandra Biswas · 2022 · Biomedicine & Pharmacotherapy
90. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer’s disease
    Neha Neha, Suhel Parvez · 2022 · Ageing Research Reviews
91. Cost‐effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    B. Rive, Dag Aarsland, Marina Grishchenko, John Michael Cochran, Michel P. Lamure, Mondher Toumi · 2011 · International Journal of Geriatric Psychiatry
92. Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update
    Dazhi Liu, Bradley P. Ander · 2012 · The Scientific World JOURNAL
93. NMDA Receptor as a Newly Identified Member of the Metabotropic Glutamate Receptor Family: Clinical Implications for Neurodegenerative Diseases
    ChiHye Chung · 2013 · Molecules and Cells
94. MRZ-99030 – A novel modulator of Aβ aggregation: II – Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice
    Gerhard Rammes, Andreas Gravius, Maarten Ruitenberg, Nico Wegener, Caroline Chambon, Kamila Sroka, Ross Jeggo, Lydia E. Staniaszek, David C. Spanswick, Eugene O‘Hare et al. · 2015 · Neuropharmacology
95. In vivo [123I]CNS‐1261 binding to D ‐serine‐activated and MK801‐blocked NMDA receptors: A storage phosphor imaging study in rats
    Remco J.J. Knol, Kora M. de Bruin, Berthe L.F. van Eck‐Smit, Sally L. Pimlott, David J. Wyper, Jan Booij · 2009 · Synapse
96. Alleviation of cognitive deficits and high copper levels by an NMDA receptor antagonist in a rat depression model
    Zhinan Li, Guodong Wang, Shuming Zhong, Xiaoxiao Liao, Shunkai Lai, Yanyan Shan, Junhao Chen, Lu Zhang, Qianyi Lu, Shiyi Shen et al. · 2020 · Comprehensive Psychiatry
97. Molecular Mimicry: Anti-DNA Antibodies Bind Microbial and Nonnucleic Acid Self-Antigens
    J. S. Rice, Czeslawa Kowal, Bruce T. Volpe, Lorraine A. DeGiorgio, Betty Diamond · 2006 · Springer eBooks
98. Chinese Medicine and Biomodulation in Cancer Patients—Part One
    Stephen M. Sagar, R.K. Wong · 2008 · Current Oncology
99. Drug reposition-based design, synthesis, and biological evaluation of dual inhibitors of acetylcholinesterase and β-Secretase for treatment of Alzheimer's disease
    Sushant Kumar Shrivastava, Avhad Ashok Nivrutti, Bhagwati Bhardwaj, Digambar Kumar Waiker, Akash Verma, Prabhash Nath Tripathi, Manish Kumar Tripathi, Poorvi Saraf · 2022 · Journal of Molecular Structure
100. Therapy of Alzheimer's disease: an update.
     Prerna Upadhyaya, Vikas Seth, Mushtaq Ahmad · 2010 · African Journal of Pharmacy and Pharmacology